International patent for RoosterRTP™ strengthen RoosterBio’s novel approaches in the growing field of Regenerative Medicine
FREDERICK, MD. (PRWEB) SEPTEMBER 30, 2019
RoosterBio Inc, a biotechnology market disrupter and leading supplier of innovative human mesenchymal stem/stromal cell (hMSC) biomanufacturing systems, today announced it has received patent approval in Australia for novel product formulations related to “Ready-to-Print” (RTP) cellular product formats (patent number AU 2015259373). This new patent adds intellectual property (IP) protection, including methods, uses and compositions in Australia. The RoosterRTP™ patent application has also been filed in the United States, Europe, South Korea, Japan, Canada, Israel and China.
“This is a significant and exciting decision for RoosterBio because this patent represents foundational technology related to biopreserved formulations of cells for tissue engineering and bioprinting applications,” said Jon A. Rowley, PhD, RoosterBio’s Founder and Chief Product Officer. “Issuance of this patent strengthens our leading intellectual property portfolio and further validates RoosterBio’s novel technology platform for accelerating regenerative medicine.”
Bioprinting of living cells and tissues creates unique product requirements related to shelf life and printability of living cells. RoosterBio was the first to launch a “ready-to-print” product formulation, RoosterRTP™, allowing bioprinters and tissue engineers to thaw and use large quantities of hMSCs for same day experiments, avoiding time-, labor- and cost-intensive cell expansion processes. “The most significant challenge in the advancement of 3D bioprinting has been the scarce availability of living cellular biomaterials for printing. Until RoosterBio, generating hMSCs would take a significant amount of time to culture and expand cells for the bioprinting process. With RoosterRTP™, we’re radically simplifying the most complex and labor-intensive aspects of bioprinting, saving users weeks of culture time and driving down the cost of cellular bioprinting.” Dr. Rowley added, “Our vision is a world where safe and effective regenerative medicines are rapidly developed and are widely available on a global scale, to benefit the lives of patients in need.”
RoosterRTP™ has been used by multiple customers, including the U.S. Military, to bring next-generation critical wound care closer to forward-deployed military positions.
For more information about RoosterRTP™, please visit https://www.roosterbio.com/collections/high-volume-hmscs.
About RoosterBio, Inc
RoosterBio, Inc. is a privately held cell manufacturing platform technology company focused on accelerating the development of a sustainable regenerative medicine industry, one customer at a time. RoosterBio’s products are high-volume, affordable, and well-characterized adult human mesenchymal stem/stromal cells (hMSCs) paired with highly engineered media systems. RoosterBio has simplified and standardized how stem cells are purchased, expanded, and used in development, leading to marked time and costs savings for customers. RoosterBio’s innovative products are ushering in a new era of productivity and standardization into the field, accelerating the road to discovery in Regenerative Medicine. For more information on RoosterBio, please visit http://www.roosterbio.com.
“Issuance of this patent strengthens our leading intellectual property portfolio and further validates RoosterBio’s novel technology platform for accelerating regenerative medicine.” Jon A. Rowley, PhD, Founder & CPO